Skip to main content

Table 4 Validation of involved pathways by in silico / in patient analyses

From: TNF-alpha and metalloproteases as key players in melanoma cells aggressiveness

Pathway name and status in A375 vs SK-Mel-28 GEO Analysis (Affymetrix)
biopsy of melanomas (n = 45) biopsy of nevi (n = 18) t test (melanomas vs nevi)
TIMP3 (Down-regulated, Illumina) 81.64 ± 9.1 92.56 ± 7.23 p value 0.00006
IL1RA (Down-regulated, Luminex) 60.02 ± 13.34 73.89 ± 12.15 p value 0.00029
VEGFA (Up-regulated, Luminex) 79.31 ± 12.39 60.78 ± 18.15 p value 0.00132
  1. Cytokines found significantly modulated in this study by transcriptomics, proteomics and/or secretome analyses comparing A375 vs SK-MEL-28 cells have been matched with transcriptomics analyses from patients biopsies (45 melanomas vs 18 nevi). In this Table the consensus is reported